For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Merck & Co., Inc. (MRK) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -16 (−100…+100 Quality+Value blend) · Quality 48 · Value -68 · Sentiment -1 (timing only, not weighted) · Composite fair value $75.49 vs $130.23 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Merck & Co., Inc.
MRK NYSEMerck & Co., Inc. operates as a leading healthcare company worldwide, specializing in the research, development, and commercialization of innovative pharmaceutical products and vaccines. Its portfolio features prominent human health pharmaceuticals such as Keytruda for oncology treatments, Welireg for specific cancer therapies, and Gardasil for HPV prevention. The company also provides a robust lineup of vaccines including ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, and Pneumovax 23, addressing infectious diseases across age groups. Additional offerings include Bridion for surgical care. Merck & Co., Inc. focuses on key therapeutic areas like oncology, vaccines, hospital acute care, and immunology, serving patients, healthcare providers, and global health systems. Through its operations, the company plays a vital role in advancing treatments for serious diseases and preventive health measures. Founded in 1891 and headquartered in Rahway, New Jersey, Merck & Co., Inc. maintains a strong presence in the biopharmaceutical sector, contributing to global health solutions.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 7.28
Total Equity: $52.66B
Shares: 2,507,000,000
Total Debt: $49.34B
Cash: $14.57B
EBITDA: $27.95B
Total Debt: $49.34B
Cash: $14.57B
Revenue: $65.01B
Revenue: $65.01B
Revenue: $65.01B
Total Equity: $52.66B
Tax Rate: 13.3%
Equity: $52.66B
Total Debt: $49.34B
Cash: $14.57B
Current Liabilities: $28.33B
Long-Term Debt: $46.75B
Total Debt: $49.34B
Total Equity: $52.66B
Shares: 2,507,000,000
Shares: 2,507,000,000
CapEx: -$4.11B
Shares: 2,507,000,000
Stock Price: $130.20
Net Income: $18.25B
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 30, 2026 9:00pm (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $48.7B | $59.3B | $60.1B | $64.2B | $65.0B |
| Cost of Revenue | $13.6B | $17.4B | $16.1B | $15.2B | $16.4B |
| Gross Profit | $35.1B | $41.9B | $44.0B | $49.0B | $48.6B |
| Operating Expenses | $21.9B | $23.6B | $41.0B | $28.8B | $26.5B |
| Operating Income | $13.2B | $18.3B | $3.0B | $20.2B | $22.1B |
| Net Income | $13.0B | $14.5B | $365.0M | $17.1B | $18.3B |
| EBITDA | $16.4B | $22.2B | $6.8B | $24.7B | $28.0B |
| EPS | $5.16 | $5.73 | $0.14 | $6.76 | $7.30 |
| EPS (Diluted) | $5.14 | $5.71 | $0.14 | $6.74 | $7.28 |
Balance Sheet (Annual)
Last updated: Jul 31, 2026 9:08am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $8.1B | $12.7B | $6.8B | $13.2B | $14.6B |
| Total Current Assets | $30.3B | $35.7B | $32.2B | $38.8B | $43.5B |
| Total Assets | $105.7B | $109.2B | $106.7B | $117.1B | $136.9B |
| Current Liabilities | $23.9B | $24.2B | $25.7B | $28.4B | $28.3B |
| Long-Term Debt | $30.7B | $28.7B | $33.7B | $34.5B | $46.8B |
| Total Liabilities | $67.4B | $63.1B | $69.0B | $70.7B | $84.2B |
| Total Equity | $38.3B | $46.1B | $37.6B | $46.4B | $52.7B |
| Retained Earnings | $53.7B | $61.1B | $53.9B | $63.1B | $73.1B |
Cash Flow (Annual)
Last updated: Jul 30, 2026 9:00pm (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | — | $19.1B | $13.0B | $21.5B | $16.5B |
| Capital Expenditure | -$4.4B | -$4.4B | -$3.9B | -$3.4B | -$4.1B |
| Free Cash Flow | — | $14.7B | $9.1B | $18.1B | $12.4B |
| Acquisitions (net) | -$179.0M | -$121.0M | $0 | -$746.0M | -$10.0B |
| Net Debt Issued / (Repaid) | -$2.3B | -$2.3B | $4.2B | $2.3B | $11.4B |
| Dividends Paid | -$6.6B | -$7.0B | -$7.4B | -$7.8B | -$8.2B |
| Stock Buybacks | -$840.0M | $0 | -$1.3B | -$1.3B | -$5.1B |
| Net Change in Cash | $14.0M | $4.6B | -$5.9B | $6.4B | $1.4B |
Growth Trends (YoY %)
Last updated: Jul 30, 2026 9:00pm (23d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +21.7% | +1.4% | +6.7% | +1.3% |
| Gross Profit Growth | +19.4% | +5.1% | +11.3% | -0.7% |
| Operating Income Growth | +38.5% | -83.8% | +584.5% | +9.3% |
| Net Income Growth | +11.3% | -97.5% | +4,589.6% | +6.6% |
| EBITDA Growth | +35.6% | -69.5% | +264.6% | +13.1% |
Dividend History (Last 20)
Last updated: Jul 31, 2026 9:08am (23d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-15 | $0.85 | — | — | — |
| 2026-03-16 | $0.85 | — | — | — |
| 2025-12-15 | $0.85 | — | — | — |
| 2025-09-15 | $0.81 | — | — | — |
| 2025-06-16 | $0.81 | — | — | — |
| 2025-03-17 | $0.81 | — | — | — |
| 2024-12-16 | $0.81 | — | — | — |
| 2024-09-16 | $0.77 | — | — | — |
| 2024-06-17 | $0.77 | — | — | — |
| 2024-03-14 | $0.77 | — | — | — |
| 2023-12-14 | $0.77 | — | — | — |
| 2023-09-14 | $0.73 | — | — | — |
| 2023-06-14 | $0.73 | — | — | — |
| 2023-03-14 | $0.73 | — | — | — |
| 2022-12-14 | $0.73 | — | — | — |
| 2022-09-14 | $0.69 | — | — | — |
| 2022-06-14 | $0.69 | — | — | — |
| 2022-03-14 | $0.69 | — | — | — |
| 2021-12-14 | $0.69 | — | — | — |
| 2021-09-14 | $0.65 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-23 02:56Even the bull case prices 30% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 87%.
| Case | Growth | Margin | Fair value | vs price ($130.23) |
|---|---|---|---|---|
| Bull — recovery | +8% | 24.1% | $91.74 | -30% |
| Base — stabilizes | +5% | 21.0% | $73.49 | -44% |
| Bear — keeps slipping | +3% | 17.8% | $57.55 | -56% |
| Stress — last quarter repeats | +4% | 4.8% | $17.24 | -87% |
Narrative Economics
market-narrative step).
Claude Reading
The Q1 2026 print is the elephant nobody in the prior models fully wrestled with: revenue collapsed to $16.29B with a $4.24B net loss — a -26% margin from a franchise that just posted 33.5% margins two quarters prior. That's not seasonality; that's either a massive one-time charge (likely an IPRD write-off from a BD deal, given Merck's history of expensing acquired R&D) or something structurally worse. The models above largely ignored this and anchored on the 2025 annual ($65.01B rev, $18.25B NI, 28% net margin) which looks pristine. If you strip the Q1 anomaly and annualize the prior four quarters, you get ~$65B revenue growing ~1.3% YoY — not the 11.2% the thesis-eval claims is priced in, and not the mid-single-digits the narrative layer assumes. Revenue has essentially flatlined: $15.62B → $15.53B → $15.81B → $17.28B → $16.40B → $16.29B. That's a rounding-error business at $65B scale.
On valuation, I partially agree with the synthesis "overvalued" call but think the $92.84 signal-adjusted fair value is too punitive for a franchise generating $12.36B FCF (a 3.8% FCF yield at $321B cap) with 34% ROE and 21.9% ROIC. Those return metrics are genuinely elite and don't deserve a distressed multiple. At 17.8x earnings and 12.9x EV/EBITDA, MRK trades below LLY (~55x), roughly in line with PFE (~15x, but declining), and at a discount to JNJ (~16x but slower growth). The real question isn't whether $130 is expensive versus a DCF — it's whether the 2028 Keytruda LOE ($29B+ franchise, ~45% of revenue) gets replaced. The bear thesis at weight 72 is correct that the replacement math is brutal: even a 30% erosion over three years post-2028 is ~$9B revenue gone, requiring the subQ formulation, Winrevair, and the oncology pipeline to collectively add $9B+ just to stand still. That's plausible but not probable.
The contrarian case the models underweight: pharma patent cliffs are almost always over-discounted in advance and under-discounted at the event. MRK executed the subcutaneous Keytruda approval (extends IP to ~2040 for the reformulation, capturing likely 40-50% of the franchise), Winrevair is ramping toward blockbuster status, and the Daiichi ADC collaboration (Enhertu-adjacent assets) is a real optionality bucket the market hasn't priced. Also missing from the bear case: the 2.59% dividend with a 45% payout ratio is well-covered by $12.4B FCF against ~$7B in dividends, leaving room for buybacks. Debt-to-equity of 0.94 with $14.6B cash and investment-grade rating means capacity for a transformative BD deal — which is exactly what a mature pharma with a cliff does. The "pipeline hasn't delivered" narrative ignores that Merck has been the most acquisitive large-cap pharma in the last 24 months.
Net verdict: I dissent partially from the synthesis. The $92-96 fair value looks like a DCF that penalizes Keytruda cliff without crediting subQ extension or BD optionality. But $130 isn't a bargain either — it's roughly fair-to-slightly-rich for what you're getting: a 3.8% FCF yield growing ~3-5%, plus a 2.6% dividend, minus real LOE risk in 2028. Fair value band is $110-120, not $93 and not $130. The Q1 2026 loss needs an explanation before I'd size up — if it's a clean IPRD charge, ignore it; if it's Keytruda pricing pressure showing up early, the bear case accelerates. I'd rate this a hold with a starter-position bias below $115, and I'd sell calls against it above $135. The synthesis is directionally right (not a buy here) but the magnitude of overvaluation is overstated by ~15-20%.
GPT Reading
Merck’s numbers read like a very good large-cap pharma business that the market is valuing like a no-drama compounder despite a very real concentration problem. The quality is obvious: 2025 revenue was $65.0B, up only 1.3% from $64.2B in 2024, but operating income still improved to $22.1B from $20.2B and net income to $18.3B from $17.1B. Gross margin remains elite at 74.8%, operating margin 34.0%, net margin 28.1%, ROIC 21.9%, and free cash flow was $12.4B on $16.5B of operating cash flow. That is exactly the profile that earns a premium in pharma. But the growth profile underneath the quality is much less exciting than the valuation implies: this is a $65B revenue company growing low single digits, not a platform compounding at 10%+. Quarterly sales over the last eight reported periods have mostly sat in a narrow $15.5B-$17.3B band. That is stability, not acceleration.
What stands out more is the earnings volatility hiding behind the “mature earner” label. The latest quarter, 2026-03-31, showed $16.29B of revenue and a startling -$4.24B net loss, versus +$5.08B in the prior-year quarter on slightly lower revenue of $15.53B. One quarter does not define the franchise, and pharma accounting often gets hit by acquisition, IPR&D, or litigation charges, but it matters because it reminds you how dependent the equity story is on confidence in normalized earnings rather than smooth observed earnings. Even excluding that, the annualized cash valuation is not obviously cheap. At $321.6B market cap, Merck trades around 17.8x earnings, 5.0x sales, and 12.9x EV/EBITDA, with a 2.6% dividend yield. Those are acceptable multiples for a durable franchise, but not for one where the central strategic issue is replacing an eventual megablockbuster decline. When a business with 4% revenue CAGR and only 1.3% recent revenue growth is priced at 5.5x EV/revenue, the market is paying in advance for pipeline execution.
The balance sheet is fine, not pristine. Debt of $49.3B against $14.6B cash leaves net debt around $34.8B; equity is $52.7B and debt/equity is 0.94. For Merck that is manageable because the cash machine is real, but it does reduce room for paying too much for external pipeline replacement. The key issue for me is that the market seems to be capitalizing current margin excellence as if it were durable through the next strategic turn. That is where I part ways. A 34% operating margin on low-growth revenue is wonderful if the product mix remains favorable; it is less bankable if the company has to spend harder on business development, absorb launch costs, or defend franchises in a tougher pricing and competitive environment. I can justify Merck as a high-quality defensive holding; I struggle to justify it at $130 as a value proposition. Fair value is closer to a market-average quality-premium pharma multiple on current cash flows, not a scarcity premium.
The best argument against this view is straightforward: Merck is exactly the kind of company investors should pay up for. Few businesses can produce $48.6B of gross profit on $65.0B of sales, convert that into $12.4B of free cash flow after $4.1B of capex, and still offer a covered dividend with a 44.8% payout ratio. The 2023 earnings collapse to just $365M now looks aberrational rather than structural, and 2024-2025 demonstrated that normalized profitability can snap back hard. If the ugly 2026 first quarter is likewise non-recurring, then the stock is not expensive at all on normalized earnings power near $18B annually. On that framing, 17.8x earnings for a recession-resistant pharma leader with strong returns on capital and deep oncology/vaccine positioning can be defended, especially if investors expect even modest external dealmaking or pipeline successes to bridge future patent exposure. A bear who focuses too much on static growth rates can miss how valuable duration and resilience are in healthcare.
What would change my mind is evidence that Merck can turn this from a low-single-digit revenue story into a genuine mid-single-digit grower without margin deterioration. Concretely, I’d want to see revenue move decisively above the current plateau—something like sustained quarterly sales above $17.5B and annual growth reaccelerating toward 5-7%—while keeping operating margin around or above 30% and free cash flow above $13B. I’d also want the next few quarters to prove the March 2026 loss was truly non-recurring, with net income normalizing back into the $4B-$5B quarterly range. Short of that, the stock looks priced for execution that the reported numbers have not yet earned.
Grok Reading
The numbers tell a clear story of a high-quality cash engine that has largely stopped growing. Merck closed 2025 with $65.01 billion in revenue, 74.8% gross margins, 34% operating margins and $18.25 billion in net income, converting that into $12.36 billion of free cash flow. ROE sits at an impressive 34.7%. Yet the top line is stagnant: revenue CAGR is only 4%, the most recent year-over-year print is 1.3%, and quarterly sales have oscillated in a tight $15.5–17.3 billion band for two years. The March 2026 quarter then delivered a $4.24 billion net loss on $16.29 billion of sales—an abrupt collapse from the prior four quarters’ 18–34% net margins. That loss is the single most important data point in the set; whether charge or early competitive leakage, it punctures the smooth-compounder narrative. At $130 the stock trades at 17.8x earnings, 5.0x sales and 12.9x EV/EBITDA. Those multiples would be defensible for a mid-teens grower; they are rich for a $65 billion franchise whose organic trajectory is barely positive and whose earnings power just swung violently negative.
Balance-sheet and cash-flow quality remain solid but not pristine. Net debt is roughly $35 billion against $52.7 billion of equity (0.94x D/E), current ratio 1.54, and operating cash flow of $16.5 billion easily covers the 45% payout and $4.1 billion capex. The 2.6% dividend yield is secure. None of that changes the valuation math. The 607% earnings CAGR is pure base-effect noise from the 2023 trough year ($365 million NI) and should be discarded; underlying earnings growth is mid-single digits at best. Paying 18x for that profile while the company’s largest product faces a well-known LOE window is the core mismatch the quantitative models correctly flag with their ~$93 fair-value estimate.
The strongest case against this read is the institutional bid for exactly this kind of cash-flow durability. A 28% net margin business that still throws off $12 billion-plus of FCF, trades at a modest discount to the 20–25x big-pharma peer group, and carries a sticky dividend will always attract defensive capital that does not require double-digit top-line growth. Keytruda combination regimens and the vaccine franchise have repeatedly pushed out the cliff timeline, and China vaccine optionality remains real. The “steady-compounder” narrative is durable precisely because the cash is real, not story. I weigh this less because relative cheapness inside an expensive sector does not repair absolute return arithmetic: 1–4% revenue growth plus multi-billion-dollar patent risk does not justify a 40% premium to DCF. The market is pricing either sustained double-digit growth from a $65 billion base or flawless pipeline replacement—neither of which the recent revenue run-rate supports.
Two things would reverse the verdict: two consecutive quarters of organic revenue growth re-accelerating above 6–7% with stable margins, or a pipeline approval/acquisition large enough to visibly offset a material slice of Keytruda before the LOE window, restoring a credible high-single-digit growth algorithm. Clean confirmation that the Q1 2026 loss was purely non-recurring with no demand softness underneath would also reduce concern.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has compounded from $48.7B (2021) to $65.0B (2025) with gross margin expanding from 72% to 74.8% and operating margin settling at 34% in 2025 (excluding the 2023 Prometheus/Imago write-down anomaly that pulled OpM to 4.9%). Net income of $18.25B on $65B revenue, FCF of $12.36B, and OCF/NI of 9.78x with accruals at -4.6% of assets point to genuine, cash-backed earnings. Beneish M of -2.27 and Altman Z of 4.18 corroborate clean earnings quality. Capital discipline is real: diluted shares actually shrank slightly (2.54B to 2.51B, -0.3% CAGR), SBC is only 1.3% of revenue, and buybacks run 264% of SBC - per-share value is being protected, not eroded. The main structural constraint is a $34.77B net debt position against only $14.57B liquid cash (4.5% of market cap), meaning the balance sheet is a working tool rather than a fortress cushion. Given $12-18B annual FCF, servicing and reducing that debt is entirely manageable. What the modules cannot see: Keytruda concentration risk and the looming loss-of-exclusivity cliff, which is the single most important quality question for Merck and one this data alone cannot resolve.
Verify before trusting this (5)
- Keytruda revenue concentration and 2028 LOE mitigation pipeline (subcutaneous formulation, next-gen IO combos)
- Debt maturity ladder and covenant profile against the $34.8B net debt
- Nature of the 2023 operating margin collapse (acquired IPR&D vs recurring)
- R&D productivity metrics and late-stage pipeline read-throughs post-Keytruda
- Animal Health / Prometheus / Daiichi collaboration economics and contingent payments
The composite fair value of $95.69 and signal-adjusted $92.84 sit ~27-29% below the $130.23 price, and the DCF ($98.71) corroborates that range. Only the anchored-PE method ($132.14) supports today's price, and that method essentially says 'the market's multiple is the market's multiple' - it is a relative anchor, not a deserved-value anchor, so it should carry less weight when the cash-flow methods disagree. The EPV floor of $53 is the earnings-power-only view stripped of growth and reflects the Keytruda-cliff downside; it is not a target, but it frames how much of today's price depends on pipeline continuation.
Verify before trusting this (4)
- Keytruda LOY mitigation strategy and subcutaneous conversion uptake in latest guidance
- Pipeline NPV disclosures / late-stage readouts that could re-rate deserved value
- Any one-time items or M&A that distorted the DCF cash-flow base
- Peer multiple compression - if the anchored-PE anchor moves, so does the only method supporting the price
The macro tape is mildly constructive (regime score +22, VIX 16, modest pullback from highs) but higher rates and a 26x market PE are ordinary crosswinds. With beta of 0.21, MRK barely registers the market's mood swings - risk-on rallies and risk-off flushes both wash over it. The narrative is a moderate-intensity, durable steady-compounder story with low cult factor: nobody is chasing this name, but nobody is dumping it either. That is the definition of balanced sentiment pressure. News flow around MRK itself is quiet - the pharma tape is dominated by GLP-1 excitement (LLY, NVO) and MRNA disappointments, both of which suck oxygen away from Merck's story rather than damage it. The pre-Q2 preview flags the familiar tensions (Keytruda strength vs Gardasil weakness, acquisition drag) without a directional lean. Analyst tone appears steady, not euphoric or capitulatory. Net: momentum has been quietly positive (+27.5pp over 3y), the story is intact but unexciting, and the low-beta profile mutes any macro press. The pressure is genuinely two-sided and modest.
Verify before trusting this (4)
- Q2 print reaction - does Gardasil weakness dominate the tape or does Keytruda strength carry it
- Any pipeline read-outs or BD moves that could inject a growth narrative and break the 'boring compounder' frame
- Whether GLP-1 rotation within pharma turns from oxygen-suck into active outflows from non-GLP-1 names
- Sell-side target revisions post-earnings - direction of drift matters more than absolute level
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 1, 2026, MRK was $130.23. We expect it to be $124.00 by Feb 2027, and we consider it great value under $100.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 1, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.